Back to Grants
Health Open for ApplicationsPAR-25-226
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Require
National Institutes of Health opportunity PAR-25-226
Eligible Applicants
Organization Types
UniversitiesNGOsSMEsGovernment Agencies
Eligible Countries / Regions
United States
Keywords
National Institutes of HealthPAR-25-226Grants.gov
Related Grants